Crinetics Pharmaceuticals, Inc. 8-K

What Happened

• Crinetics Pharmaceuticals, Inc. filed an 8-K on Jan 7, 2026 disclosing an underwriting agreement dated Jan 6, 2026 with Leerink Partners LLC and J.P. Morgan Securities LLC. The company is offering 7,620,000 shares of common stock at $45.95 per share.
• The underwriters will buy the shares from the company at $43.42275 per share and have a 30‑day option to purchase up to 1,143,000 additional shares. The offering is expected to close on Jan 8, 2026, subject to customary conditions.

Key Details

• Shares offered: 7,620,000 common shares; option for +1,143,000 shares (30 days).
• Price to public: $45.95 per share; underwriter purchase price: $43.42275 per share.
• Expected net proceeds: approximately $330.2 million (or approximately $379.8 million if the option is fully exercised).
• Offering made under the company’s Form S-3 shelf registration (No. 333-280407); legal opinion from Morrison & Foerster LLP included.

Why It Matters

• The offering will raise substantial cash for Crinetics (approx. $330M–$380M), which can affect the company’s financial resources and runway.
• New shares increase the company’s outstanding common stock, so investors should account for potential dilution if the offering and option are executed.
• The transaction is subject to closing conditions and standard underwriting terms; the filing also includes customary forward‑looking statement disclosures.